IsoPlexis Roundtable/Literature Review - ii

Expert Panel
Dr. Julianna LeMieux (moderator) started her career on a traditional scientific academic
path, earning a PhD from the Department of Molecular Biology and Microbiology at Tufts
Medical School where she studied the pathogenic bacterium Streptococcus pneumoniae.
From there, she was a postdoctoral associate in the Department of Biology at MIT studying
host-pathogen interactions using Caenorhabditis elegans. She then taught full time for
several years, including serving as a faculty member in the Citizen Science program at Bard
College both on campus and at the Taconic Correctional Facility through the Bard prison
initiative. After several years of teaching, she sought to move out of the classroom to be at the
forefront of the work centered on the communication of science. She has been writing ever
since and joined the editorial team at GEN as a science writer in 2018. At GEN, she covers
many aspects of biology including genomics, genome editing, cancer, and infectious disease.
Dr. James R. Heath is president and professor at Institute for Systems Biology in Seattle.
Heath also has the position of professor of molecular and medical pharmacology at UCLA,
and he has directed the National Cancer Institute-funded NSB Cancer Center since 2005.
Formerly, he was the Elizabeth W. Gilloon Professor of Chemistry at Caltech, and served as
codirector of the Parker Institute for Cancer Immunotherapy at UCLA until 2017. Heath
received his PhD in 1988 from Rice University, where he was the principal graduate student
involved in the discovery of C60 and the fullerenes. He was a Miller Fellow at UC Berkeley
before joining the research staff at IBM Watson Labs in 1991. He took a faculty position at
UCLA in 1994, and moved to Caltech in 2003. He has received several awards and honors,
including the Irving Weinstein Award from the American Association of Cancer Researchers, and the Sackler Prize in the physical sciences. He was named one of the top seven
innovators in the world by Forbes Magazine. Heath has founded or cofounded several
companies, including PACT Pharma, Integrated Diagnostics, Indi Molecular, CTI Molecular Imaging (acquired by Siemens in 2005), Sofie Biosciences, IsoPlexis, and NanoSys.
Dr. Naval Daver is an associate professor and director of the Leukemia Research Alliance
Program in the Department of Leukemia at MD Anderson Cancer Center. He completed his
medical school from Grant Medical College and Sir J J Group of Hospitals, Mumbai, followed
by a residency and fellowship in hematology-oncology from Baylor College of Medicine. He is a
clinical investigator with a focus on molecular and immune therapies in AML and myelofibrosis
and is principal investigator on over 25 ongoing institutional, national, and international clinical
trials in these diseases. These trials focus on developing a personalized therapy approach by
targeting specific mutations or immune pathways expressed by patients with AML, evaluating
novel combinations of targeted, immune, and cytotoxic agents, and identifying and overcoming
mechanism of resistance. He is especially interested in developing monoclonal and bispecific
antibodies, immune checkpoint, and vaccine-based approaches, as well as targeted and apoptotic
therapies in AML and is leading a number of these trials at MDACC. Dr. Daver has published
over 200 peer-reviewed articles and is on the editorial board of numerous hematology-specific
journals. He has also authored numerous abstracts at national and international conferences.

IsoPlexis Roundtable/Literature Review

Table of Contents for the Digital Edition of IsoPlexis Roundtable/Literature Review